Edition:
United States

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

6.05USD
19 Jun 2018
Change (% chg)

$-0.05 (-0.82%)
Prev Close
$6.10
Open
$6.05
Day's High
$6.10
Day's Low
$5.97
Volume
54,926
Avg. Vol
105,981
52-wk High
$9.85
52-wk Low
$5.05

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update
Monday, 12 Mar 2018 07:05am EDT 

March 12 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE.CORBUS PHARMACEUTICALS HOLDINGS INC - CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2017 WAS APPROXIMATELY $62.5 MILLION.CORBUS PHARMACEUTICALS - EXPECTS CURRENT CASH ON HAND, EXPECTED MILESTONE PAYMENTS TO FUND OPERATIONS THROUGH Q4 OF 2019.  Full Article

Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​
Friday, 5 Jan 2018 05:10pm EST 

Jan 5 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​.  Full Article

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 08:05am EST 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article

Corbus Pharma prices underwritten public offering of common stock
Tuesday, 24 Oct 2017 09:06am EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock.Says public offering of 4.65 million common shares priced at $7.00 per share.  Full Article

Corbus Pharmaceuticals Holdings announces proposed public offering of common stock
Monday, 23 Oct 2017 04:01pm EDT 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock.Corbus Pharmaceuticals Holdings Inc - ‍Corbus intends to use proceeds of proposed offering to fund its continued development of anabasum, among others​.  Full Article

Corbus Pharma's inflammatory disease drug succeeds mid-stage study
Thursday, 19 Oct 2017 07:30am EDT 

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​.  Full Article

Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15
Wednesday, 9 Aug 2017 07:05am EDT 

Aug 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update.Q2 loss per share $0.15.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Corbus Pharmaceuticals Holdings Inc - ‍ended Q2 with approximately $43.0 million of cash and cash equivalents​.  Full Article

Corbus Pharmaceuticals Q1 loss per share $0.16
Tuesday, 9 May 2017 09:00am EDT 

May 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::Corbus Pharmaceuticals reports 2017 first quarter financial results and provides business update.Q1 loss per share $0.16.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Company ended quarter with $49 million of cash which is sufficient to fund operations through end of 2018.  Full Article

Corbus Pharma outlines U.S. approval path for anabasum
Wednesday, 5 Apr 2017 08:30am EDT 

Corbus Pharmaceuticals Holdings Inc : Corbus Pharmaceuticals to commence single Phase 3 study of anabasum for treatment of systemic sclerosis after guidance from end-of-phase 2 meeting with FDA . Expects to enroll its first patient in single phase 3 study in fourth quarter of 2017 . Engaging EMA for discussing clinical development of anabasum to support application for marketing approval to treat systemic sclerosis .Plans to complete enrollment of 52-week Phase 3 international study in 2018 with results expected in 2019, NDA application thereafter.  Full Article

BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21

* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE